EcoDrugPlus

Poly(Adp-Ribose) Polymerase Family Member 3

Ensembl ID : ENSPNYG00000006648
Gene Symbol: PARP3
3 Cross references
197 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSPNYG00000024122
Gene Symbol: PORCN
3 Cross references
197 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSPNYG00000015008
Gene Symbol: PORCN
3 Cross references
193 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSPNYG00000020092
Gene Symbol: KCNMA1
3 Cross references
239 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSPNYG00000011210
Gene Symbol: KCNMA1
3 Cross references
235 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily N Member 4

Ensembl ID : ENSPNYG00000003219
Gene Symbol: KCNN4
2 Cross references
187 Possible Orthologues:

Potassium Channel Subfamily K Member 2-Like

Ensembl ID : ENSPNYG00000017023
Gene Symbol: LOC102196356
2 Cross references
209 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSPNYG00000021785
Gene Symbol: KCNJ11
1 Cross references
188 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSPNYG00000019341
Gene Symbol: KCNJ2
3 Cross references
202 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2a

Ensembl ID : ENSPNYG00000020001
Gene Symbol: KCNJ2A
1 Cross references
207 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSPNYG00000001943
Gene Symbol: KCNJ3
3 Cross references
224 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 5

Ensembl ID : ENSPNYG00000012314
Gene Symbol: KCNJ5
3 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).